The CLEAN-DUCT / TRITICC-3 Trial - Phase IIa, Prospective, Single Arm, Open Label, Non-randomized, Multi-center Pilot Study of Durvalumab (MEDI4736) + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma
The present clinical trial is a prospective, investigator-initiated, single-arm, open-label, multicenter phase II trial. Patients with unresectable perihilar and/or ductal CCA with indication for bile duct stenting and palliative systemic therapy as determined by the local multidisciplinary team (MDT), who already resolved cholestasis due to RFA + Stent will be enrolled. We hypothesize that in patients with extrahepatic cholangiocarcinoma, the use of a combination radiofrequency ablation followed by systemic treatment with chemotherapy plus durvalumab might further increase the anti-tumor activity.
Radiochirurgie beim Nierenzellkarzinom: Daten der multizentrischen prospektiven FASTRACK II-Studie
Article
作者: Trommer, Maike ; Morgenthaler, Janis ; Kirste, Simon ; Rühle, Alexander
2024-07-01·Strahlentherapie und Onkologie
Radiotherapy plus durvalumab for the treatment of locally advanced non-small cell lung cancer—The DOLPHIN trial
Article
作者: Trommer, Maike
2024-07-01·Die Urologie
Multizentrische Netzwerke, innovative Konzepte und klassische Grundlagenforschung – die Mischung macht es: Bericht über die 14. Jahrestagung des Deutschen Forschungsverbundes Blasenkarzinom e. V. (DFBK) in Köln
作者: Ecke, Thorsten H ; Gaisa, Nadine T ; Wirtz, Ralph M ; Hoffmann, Michèle J ; Heidenreich, Axel ; Füssel, Susanne ; Nawroth, Roman